Systemic drug pricing reform under Trump highlights structural inequities in healthcare access
Original framing: “STAT+: Pharmalittle: We’re reading about Trump’s drug pricing moves, a GSK asthma drug, and more” — STAT News
Drug pricing in the U.S. is an outlier compared to other developed nations. Cross-cultural analysis shows that countries with centralized healthcare systems negotiate better prices and have more equitable access to medicines.
The push for 'most-favored nation' drug pricing under Trump reveals a deeper conflict between corporate power and public health.
Historical precedents and cross-cultural models demonstrate that systemic reform is possible through transparent pricing, expanded generic production, and the inclusion of indigenous and traditional knowledge. By addressing the structural incentives that allow pharmaceutical companies to maintain high prices, policymakers can create a more equitable healthcare system. The voices of marginalized communities, often excluded from these debates, must be central to shaping a future where healthcare is a right, not a privilege.